Skip to content

Study · Animal study (in vivo) · rat · 2024

1 result

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats.

Wells RG, Azzam AF, Hiller AL, Sardinia MF

Journal of Huntington's disease1 Jan 2024Cited by 1 (Europe PMC)

PMID38489193 (opens in a new tab)DOI10.3233/jhd-231507 (opens in a new tab)PepBankPUB-38489193
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to 3-NP, PNB-0408 did not protect against the induced deficits compared with 3-NP exposure alone.

    In plain wordsIn rats, PNB-0408 did not protect against deficits compared with 3-NP exposure alone.

    Peptide
    Dihexa
    Outcome
    No significant change3-NP-induced deficits
    Study

    Ratn: not reported in source

    Male Wistar rats exposed to 3-NP
    Comparator
    3-NP group
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    From our observations and analysis, PNB-0408 did not protect rats from the deficits induced by 3-NP neurotoxicity.
    3 context sentences
    Summary · context
    Forty male Wistar rats were randomized into three groups consisting of a "vehicle" group, a "3-NP" group, and a "3-NP + PNB-0408" group.
    Summary · context
    PNB-0408 was administered along with chronic exposure to 3-NP.
    Summary · context
    Animal body weight, motor function, and cognitive abilities were measured for five weeks, before euthanasia and histopathological analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:45 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.